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Abstract
More than a dozen substances are meanwhile available for the disease-modifying immunotherapy of multiple sclerosis (MS).
However, for some substances, there is a clear difference between approval in Switzerland (Swissmedic) and neighboring
countries (EuropeanMedicines Agency (EMA)). In addition, limitations imposed by the Swiss Federal Office of Public Health in
the specialties list (SL) have significant effects on use in daily clinical practice. In the following, we present consensus recom-
mendations, whichwere reviewed and agreed upon by the Scientific Advisory Board of the SwissMultiple Sclerosis Society and
the Swiss Neurological Society.We explicitly focus on practice-relevant differences in the approval of MS immunotherapies in
Switzerland compared with the EMA area and discuss further limitations (SL) and their impact on the use in clinical practice.
Immunotherapies with the same approval in Switzerland and the EMA area and symptomatic therapies are not discussed here.
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Introduction
There is hardly any field of neurology where therapeutic
progress has been so clearly tangible as the immunotherapy
of multiple sclerosis (MS). More than a dozen substances
with different mechanisms of action, modes of administra-
tion, target groups, and benefit-risk profiles have now been
approved for relapsing forms of MS. Additionally and for
the first time, a drug that alters the disease course is avail-
able for primary progressive MS, which could not be
treated with immunotherapy until recently. However, the
approval of individual substances can vary widely in dif-
ferent countries. This is particularly important for Swit-
zerland due to various considerable differences in
approval (e.g. first-line vs. second-line treatment) in
directly neighboring countries (EMA approval area). In
addition, there are different safety requirements for some
substances. Furthermore, independently of the benefit-
risk assessment as part of approval in Switzerland, there
is a procedurally and institutionally separate cost-benefit
assessment by the Swiss Federal Office of Public Health
(FOPH) that is reflected in the specialties list (SL). The SL
lists the medications reimbursed by the compulsory health
insurance as well as potential limitations. The specific
regulatory conditions in Switzerland lead to partly differ-
ent usage in routine clinical practice that is not reflected in
European or other national guidelines to date. This struc-
tured commentary aims to discuss immunotherapeutic
drugs for which particular approval, safety requirements,
or limitations in the SL exist in Switzerland. For this,
specific features of the definitions (e.g. regarding disease
activity) are considered and potential differences with the
clinical study data discussed. The commentary focuses on
patient selection and safety considerations that underlie
approval or respective restrictions in Switzerland. If rele-
vant, also aspects of reimbursement are discussed. The
following substances are reviewed (in alphabetical order,
substance/trade name®): alemtuzumab (Lemtrada®), cla-
dribine (Mavenclad®), daclizumab (Zinbryta®), fingoli-
mod (Gilenya®), and ocrelizumab (Ocrevus®). For
methodological reasons, substances that have been
approved in the EMA area but not yet in Switzerland
(cladribine, Mavenclad®) or that have been withdrawn
from the market but previously had partly different usage
in Switzerland compared to the EMA area (daclizumab,
Zinbryta®) are also included. As autologous hematopoie-
tic stem cell transplantation (aHSCT) was approved for
reimbursement with limitations in Switzerland in July
2018 but is handled differently in most countries within
the EMA approval area, we have also included a short
section on aHSCT.
For the remaining substances that are used in the
same way as in the EMA approval area, we refer to
respective current guidelines.1 Similarly, also sympto-
matic treatment and acute treatment of MS relapses are
not discussed here.
Methods
The group of authors comprises members from French-,
German-, and Italian-speaking parts of Switzerland. Neu-
rologists from centers focusing on the treatment of MS
were invited to participate in the development of the
manuscript. The neurologists were from university and
non-university centers as well as from the outpatient sec-
tor. All members of the Scientific Advisory Board of the
Swiss MS Society (SMSS) were also invited to participate
in drafting the document. Under the coordination of the
corresponding author (AC), at least two authors wrote a
commentary on a substance in their respective mother
language. In addition to the cited literature, the commen-
tary was based on the current Swiss information for
health-care professionals (Swissmedic), the summary of
product characteristics (SmPC, EMA), and the FOPH’s
SL. No systematic literature review was performed. All
the commentaries were integrated and then revised by
other members of the author group who had not been
involved in the initial drafting. In a consensus, all authors
approved the revised version; however, formal criteria
were not employed (e.g. DELPHI method). The metho-
dology therefore involved structured commentaries by the
authors but without following formal requirements of a
guideline process.
The manuscript was then submitted to the Scientific
Advisory Board of the Swiss MS Society and the Swiss
Neurological Society (SNS) for further comments. The
final version was then translated into French, German, Ita-
lian, and English.
We focused on aspects that are different for health-care
professionals in Switzerland compared to the EMA area or
that the authors consider particularly relevant for Switzer-
land in terms of the indication, specific safety aspects or
formal requirements. The commentaries for the individual
substances are structured as follows:
 substance/trade name;
 comparative table of indication according to Swiss
information for health-care professionals, the SL
published by the Swiss FOPH and the indication
according to the EMA (SmPC); as no English ver-
sion exists of the Swiss information for health-care
professionals and the SL, authors translated the rel-
evant sections from German into English;
 considerations on patient selection;
 considerations on safety aspects; and
 considerations on confirmation of cost coverage/
reimbursement (if applicable).
Due to the withdrawal from the market of daclizumab
and current lack of approval for cladribine tablets in Swit-
zerland, this structure was not used for these substances.
Both the Swiss Multiple Sclerosis Society and the Swiss
Neurological Society supported the preparation of this
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commentary through translation and other administrative
work. Potential conflicts of interest for each individual
author were controlled by the Ombuds Committee of the
Swiss Multiple Sclerosis Society.
Commentary on individual substances
Alemtuzumab (Lemtrada®)
Commentary
Considerations on patient selection: RRMS. The definition of
disease activity in the Swiss information for health-care
professionals is completely clinical, based on relapses,
regardless of any previous treatment. In addition, there is
a limitation in the SL, whereby alemtuzumab should be used
for previously untreated patients with a primary highly
active disease course, without further definition. The SL also
mentions treatment failure under prior immunotherapy as a
further possibility for using the treatment, without giving
details such as the time interval or type of previous therapy.
In contrast to the Swiss approval, EMA has a relatively open
indication for active RRMS that is not further defined. In
addition, in the EMA area, imaging and clinical parameters
can be used for the assessment of disease activity.
The above-mentioned criteria partly correlate with the
inclusion criteria of the pivotal studies. One study (CARE
MS I) included patients without prior immunotherapy who
had experienced at least two relapses in the preceding 2
years and at least one relapse in the previous year (corre-
sponding to the approval by Swissmedic).5 A separate
study (CARE MS II) included patients with prior immu-
notherapy who had suffered from at least two relapses in
the preceding 2 years, including at least one relapse in the
previous year, of which at least one relapse while on inter-
feron- or glatiramer acetate therapy after at least 6 months
of treatment.6 These criteria are partly reflected in the SL,
which does not, however, specify the prior therapy. This
mirrors clinical practice, so that in our opinion treatment
failure should not be limited to prior therapy with inter-
feron- or glatiramer acetate but should also apply to other
approved immunotherapies for MS.
As regards to the definition of disease activity according
to Swiss information for health-care professionals, it should
be noted that aspects such as the severity of the relapse are
not considered. On the other hand, the more open definition
of disease activity in the EMA area places higher demands
on the prescribing doctor in terms of the individual benefit-
risk evaluation.
Considerations on safety aspects
For general safety considerations, we refer to the informa-
tion for health-care professionals. Among other aspects, the
information for health-care professionals stipulates that
treatment must be started and monitored by a neurologist
experienced in the treatment of MS patients. Under alem-
tuzumab, even several months after the transition from
natalizumab (Tysabri®) (“carry over”) progressive multi-
focal leukoencephalopathy (PML) is possible. To reduce
this risk, we recommend magnetic resonance imaging
(MRI) of the brain (cranial MRI, including contrast agent
and diffusion weighted imaging) close to the start of treat-
ment with alemtuzumab. The evaluation should preferably
be carried out by a (neuro-) radiologist experienced in the
diagnosis of inflammatory diseases of the central nervous
system. For patients with a high risk of developing PML
(positive serum anti-JCV antibodies, treatment duration
with natalizumab 2 years; or previous immunosuppres-
sion), it is also recommended to carry out a cranial MRI
after start of the treatment. Additionally for this patient
group, a lumbar puncture to determine JC virus DNA, pre-
ferably in a high sensitivity assay, is advisable prior to
treatment start. Because fingolimod can also increase the
Indication according to Swiss information
for health-care professionals (translation
from the Swiss Fachinformation2)
Indication according to the
Swiss SL (translation from the
Swiss SL3)
Indication according to the
SmPC (EMA)4
Lemtrada is used in adults with active,
relapsing-remitting multiple sclerosis,
defined by at least two clinical relapse
events within the 2 years preceding the
start of treatment, of which at least one
relapse in the year before the start of
treatment.
As monotherapy for active relapsing
remitting multiple sclerosis (RRMS)
despite treatment with at least one basic
therapeutic agent or in previously
untreated patients with a primary highly
active form after prior confirmation of
cost coverage by the independent
medical examiner.
Dosage: five infusions in the first year and
three infusions in the second year.
Treatment by specialist neurologist
(FMH) with timely access to magnetic
resonance imaging (MRI).
Lemtrada is indicated for adult patients
with relapsing remitting multiple
sclerosis (RRMS) with active disease
defined by clinical or imaging features.
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risk of PML (see below), we recommend to perform a
cranial MRI during the switch from fingolimod to alemtu-
zumab, as described above. Some centers similarly perform
lumbar puncture when switching from fingolimod to alem-
tuzumab, but there is no consensus regarding this approach
among Swiss centers.
Overall, the approach described to reduce the risk of
developing PML as part of a treatment switch is not evi-
dence based but follows previous experience and considers
the pathophysiological development of PML.7
Because of single cases of listeriosis and listeria
meningitis under treatment with alemtuzumab, no raw
or undercooked meat, soft cheese, and unpasteurized dairy
products should be consumed for 4 weeks after the last
infusion, according to Swiss information for health-care
professionals. The SmPC in the EMA area recommends
avoiding consumption of the above-mentioned foods as
early as 2 weeks before the start, during and for at least
1 month after alemtuzumab infusion therapy. We support
this recommendation because of the incubation time of
listeriosis. The combination of sulfamethoxazol and tri-
methoprim can be considered for 1 month after the start of
treatment.
Considerations on confirmation of cost
coverage/reimbursement
According to the SL, confirmation of cost coverage is
required for patients with a highly active disease form
who have not received prior treatment. It is essential to
note that no generally accepted definition of the term
“highly active” exists and that assessment depends on the
individual situation. This is therefore a judgement call,
which is subject to appropriate assessment in individual
cases. The treating physician makes this judgement call.
Confirmation of cost coverage should not lead to a time
delay with this urgent treatment for a vulnerable patient
group.
Autologous hematopoietic stem cell
transplantation (aHSCT)
Commentary
aHSCT is approved for scleroderma as an autoimmune
disease. Within the EMA area, aHSCT is available as an
approved treatment procedure for MS in few countries
(e.g. Sweden) or can be used after expert opinion in some
regions but is not authorized in other countries. In Swit-
zerland, intensive immunosuppression followed by
aHSCT for MS was approved for compulsory health insur-
ance reimbursement by the Swiss FOPH on July 1, 2018,
on conditions (e.g. recording of patients treated in a reg-
istry). The relevant details are currently being established
and the registry is being created. Because of the available
treatment alternatives, particularly for relapsing disease
forms, the present lack of controlled, randomized studies
of highest evidence class and the invasive nature of treat-
ment with potentially severe side effects, this treatment is
subject of controversial debate in Switzerland. The treat-
ment should therefore currently only be used in carefully
selected cases. Relevant criteria include, for example,
highly active disease, low or moderate degree of disability
up to EDSS 6.5, patients aged up to 50 with disease dura-
tion of not more than 10 years, and failure of previous
highly active approved treatment.9,10 Because the treat-
ment recommendation regarding aHSCT needs to be mul-
tidisciplinary and individualized, we recommend
assessment at specialized academic centers only. For
details of the therapy and current evidence on the effec-
tiveness and side effects, we refer to respective refer-
ences.9–11
Cladribine (Mavenclad®)
Commentary
A parenteral form of cladribine is authorized in Switzerland
for the treatment of hairy cell leukemia. The use of cladri-
bine tablets to treat MS has been submitted to Swissmedic
for approval in Switzerland. In the EMA area, Cladribine
tablets have been approved for treating adult patients with
highly active relapsing multiple sclerosis, defined by clin-
ical or imaging findings, since August 2017.12 The treat-
ment is administered orally and comprises two short
treatment cycles within two successive years at a cumula-
tive dose of 3.5 mg/kg body weight.13 The tablets are admi-
nistered over a few weeks at the start of the respective
treatment year. Retreatment in years 3 and 4 is not regularly
scheduled.
According to the SmPC in the EMA approval area, con-
traindications comprise hypersensitivity to the active sub-
stance/excipients, HIV infection, active chronic infections
(tuberculosis, hepatitis), initiation in immunocompromised
patients, active malignant tumors, moderate-to-severe
impairment of kidney function as well as pregnancy and
breastfeeding.
Ordinance of the Federal Department of Home Affairs regarding
benefits of the Compulsory Health Insurance
(Health Insurance Benefits Ordinance, HIBO) of September 29,
1995 (as of January 1, 2019) (Translation)8
Hematopoietic stem cell transplantation: Procedure: Autologous
hematopoietic stem cell transplantation: yes
Requirements: in evaluation—for MS at the University Hospital
Zurich as part of a registry study.
Indication by interdisciplinary MS stem cell transplantation board
of University Hospital Zurich. Valid from July 1, 2018 until June
30, 2024
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Daclizumab beta (Zinbryta®, withdrawn
from the market since March 2018)
Commentary
The monoclonal antibody daclizumab against the alpha
subunit of the high-affinity IL2 receptor CD25 was
approved by the EMA and Swissmedic in 2016 for treat-
ment of adult patients with relapsing forms of multiple
sclerosis. Already in the pivotal studies, there was evidence
of autoimmune side effects under daclizumab therapy. The
most prominent were autoimmune skin reactions with
sometimes severe course. In addition, there were cases of
autoimmune hepatitis (including one fatal case) and
inflammatory bowel disease. After approval, further cases
of these autoimmune adverse drug reactions were reported,
including an additional case of fulminant hepatitis with
liver failure, which proved fatal. This led to restrictions
on approval in the EMA area as early as 2017, whereby
daclizumab could only be used as a third-line treatment.14
Subsequently, further cases of meningitis and encepha-
litis were reported, for which the pathomechanism under
daclizumab is unclear. Some of these cases were fatal.
Brain biopsies showed infiltration with eosinophil granu-
locytes, which is not consistent with MS-typical pathology.
Because of additional symptoms such as fever, generalized
rashes, and eosinophilia, a “drug reaction with eosinophilia
and systemic symptoms (DRESS)” involving the CNS was
suspected. In addition, cases with anti-N-methyl-D-
aspartate (NMDA) receptor antibody-mediated autoim-
mune encephalitis with symptoms appearing 3–4 months
after discontinuing daclizumab were reported.15 With the
current state of knowledge, individual risk cannot be pre-
dicted for either autoimmune hepatitis or encephalitis. It
was therefore not possible to develop an adequate risk
management plan. Because of these serious side effects
without any possibility of individual risk assessment, the
Pharmacovigilance Risk Assessment Committee (PRAC)
of the EMA recommended that authorization be stopped.
The manufacturer thereupon removed daclizumab from the
market worldwide in March 2018.16 After treatment with
daclizumab is stopped, close clinical and monthly labora-
tory monitoring of these patients for at least 12 months after
the last dose of daclizumab should be carried out. In case of
typical symptoms (e.g. behavioral symptoms, cognitive
symptoms, movement disorders, and seizures), anti-
NMDA receptor antibody-mediated encephalitis should
be considered, with appropriate further diagnosis and treat-
ment carried out at a specialized center.
Fingolimod (Gilenya®)
Commentary
Considerations on patient selection: RRMS
Phase III clinical studies have evaluated the effectiveness of
fingolimod in RRMS: two trials against placebo,
FREEDOMS20 and FREEDOMS II,21 and one study with
Interferon--1a (30 mg im, intramuscular) as a comparator:
TRANSFORMS.22 The inclusion criteria of the three studies
were similar: patients with 2 relapses in the two previous
years or 1 relapse in the preceding year. The decision to
use fingolimod as a first-line treatment (in Switzerland) ver-
sus second-line (EMA) is probably based on a different
benefit-risk assessment of the treatment and on the interpre-
tation of the characteristics of the patients in the studies: 57%
of patients received the therapy as a first-line treatment in
FREEDOMS versus 45% in TRANSFORMS.
Indication for children (<18 years) RRMS: according to
the manufacturer (Novartis, communication 25. 1. 2019)
fingolimod was approved by Swissmedic for paediatric
patients aged 10 years and above (PARADIGMS trial).23
Indication according to Swiss information for health-
care professionals (translation from the Swiss
Fachinformation17)
Indication according to the
Swiss SL(translation from
the Swiss SL18)
Indication according to the
SmPC (EMA)19
Gilenya is indicated for the treatment of patients
with relapsing remitting multiple sclerosis (MS)
for the reduction of relapse rate and delay of
disability progression.
Treatment of relapsing
remitting multiple
sclerosis.
Initial prescription by a
specialist neurologist
(FMH).
Gilenya is indicated as single disease modifying
therapy in highly active relapsing remitting
multiple sclerosis for the following groups of adult
patients and paediatric patients aged 10 years and
older:
Patients with highly active disease despite a full
and adequate course of treatment with at
least one disease modifying therapy or
Patients with rapidly evolving severe relapsing
remitting multiple sclerosis defined by 2 or
more disabling relapses in one year, and with
1 or more Gadolinium enhancing lesions on
brain MRI or a significant increase in T2 lesion
load as compared to a previous recent MRI.
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Considerations on safety aspects
For general safety considerations, we refer to the informa-
tion for health-care professionals, mainly as regards heart
rate monitoring for the first dosing and cardiac contraindi-
cations, ophthalmological controls (macular edema, partic-
ularly in patients with diabetes or uveitis) and the
vaccination recommendations for patients with negative
serological antibody testing for varicella zoster virus.
Although the SL requires initial prescription by a neurolo-
gist, we deem continued regular specialist neurological
monitoring essential because of rare but potentially severe
side effects.
Cases of PML have recently been reported under fingo-
limod.24 Nineteen cases of PML (after excluding “carry
over” effects of natalizumab, Tysabri®) have been reported
with an overall risk of 1/15,000 MS patients treated.25
Eighteen of the nineteen patients suffering from PML were
aged >40 and 18 of the 19 had >2 years of treatment with
fingolimod. An increasing number of cases of cryptococcal
infections including meningitis have been reported in the
postmarketing setting.26 Most of the cryptococcal menin-
gitis cases were reported in patients >40 and who had
received treatment for >2 years.27 Although limited, cur-
rent data suggest that the patients’ age could constitute a
risk factor. However, as with other studies with disease-
modifying treatment, patients aged >55 were not included
in the fingolimod studies. In addition, the role of immuno-
senescence in the context of immunosuppressive therapies
has not been studied in depth.24,25,27
Risk stratification for PML under fingolimod has not
been validated to date. As with all disease-modifying thera-
pies, we suggest a reference brain MRI scan before starting
treatment and regularly thereafter, for example, at yearly
intervals. For patients with an increased PML risk, for exam-
ple, after previous therapy with natalizumab (Tysabri®),
more frequent MRI scans should be considered. Some cen-
ters in Switzerland perform the antibody blood test against
JC virus (STRATIFYJCV™) under fingolimod and observe
that anti-JCV antibodies are detected under this treatment.
These centers adapt their care and monitoring depending on
the results of this test (e.g. increased radiological monitoring,
change of treatment) in patients > 45years old who have
received treatment for >2 years.28 There is no consensus
on this approach among Swiss centers.
Ocrelizumab (Ocrevus®)
Commentary
Considerations on patient selection: relapsing MS
(RMS)
The Swiss and European approval relate to relapsing
courses in contrast to relapsing remitting disease courses.
The Swiss information for health-care professionals states
active forms but does not further define this term. In March
2018, ocrelizumab was included in the SL for this indica-
tion without restrictions.
The European EMA approval is substantially different.
The EMA’s approval refers to the patient spectrum of the
pivotal studies (OPERA I and II: activity defined as at least
two relapses in the previous 2 years or one relapse in the
preceding year; EDSS between 0 and 5.5).32 The majority of
patients investigated (>70%) were treatment naive.
Although clinical relapse activity represented the key inclu-
sion criterion in the pivotal studies, we agree that MRI ima-
ging activity can also form the basis for treatment. However,
methodological limitations concerning MRI activity in clin-
ical practice should be critically considered. Clinical routine
often does not sufficiently ensure standardization of consec-
utive MRI investigations (e.g. field strengths and equipment,
repositioning, and protocols). This should be considered
when comparing images, for example, for increase in lesion
burden. In clinical practice additional, often highly indivi-
dualized aspects play a role when assessing disease activity.
These include, for example, duration and degree of recovery
from relapses and residual functional limitations relevant for
activities of daily living or occupation.
Indication according to Swiss information
for health-care professionals (translation
from the Swiss Fachinformation29)
Indication according to the
Swiss SL (translation from the
Swiss SL30)
Indication according to the
SmPC (EMA)31
Ocrevus is indicated for the treatment of
adult patients with active relapsing forms
of multiple sclerosis (MS).
Ocrevus is indicated for the treatment of
adult patients with primary progressive
multiple sclerosis (PPMS) to slow down
disease progression and reduce the
deterioration in walking speed.
Restriction until February 29, 2020
For the treatment of adult patients with
active relapsing forms of multiple
sclerosis (MS).
For the treatment of adult patients with
primary progressive multiple sclerosis
(PPMS) to slow down disease
progression and reduce the
deterioration in walking speed.
Ocrevus is indicated for the treatment of
adult patients with relapsing forms of
multiple sclerosis (RMS) with active
disease defined by clinical or imaging
features.
Ocrevus is indicated for the treatment of
adult patients with early primary
progressive multiple sclerosis (PPMS) in
terms of disease duration and level of
disability, and with imaging features
characteristic of inflammatory activity.
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Primary progressive MS
The Swiss information for health-care professionals does
not restrict usage regarding the disease duration, degree of
disability, or activity on MR-imaging. Preserved ambula-
tion is implicit in the Swiss approval, but this is not more
closely defined (e.g. regarding walking aids). In addition,
the general delay of disease progression is also stated in the
information for health-care professionals. Accordingly,
ocrelizumab has been included in the SL for PPMS since
March 2018 without further restrictions. The EMA
approval restricts usage in line with the pivotal study.33
This approval study included patients aged below 55 with
a disease duration of <15 years and an EDSS between 3 and
6.5. Focal inflammatory activity on imaging represents a
particular feature, which is obligatory according to the
EMA approval text but not according to the Swiss infor-
mation for health-care professionals.
Because no immunotherapeutic alternatives exist for
PPMS, the Swiss approval without further restrictions in
the SL is reasonable. A delay in disease progression not
only does involve patients with preserved ambulation but
also preservation of other relevant residual functions can be
a treatment target (e.g. arm function, fine motor skills).
Detailed assessment of the disease progression in a quanti-
tative fashion is important both before and during treatment
(EDSS, multiple sclerosis functional composite with timed
25-foot walk, 9 hole peg test). Younger patients with
shorter disease course and focal inflammatory activity as
evidenced by imaging (gadolinium enhancing lesions on
MRI) seem to particularly benefit from the treatment; how-
ever conversely, this does not mean that patients without
such MRI abnormalities should automatically be excluded
from this treatment.
Considerations on safety aspects
For general safety considerations, we refer to the informa-
tion for health-care professionals. Among other aspects, the
information for health-care professionals stipulates that
treatment must be started and monitored by a neurologist
experienced in the treatment of MS patients. Under ocreli-
zumab, “carry over” cases of PML have been reported after
transition from both natalizumab and fingolimod. To
reduce this risk, we recommend MRI of the brain (cranial
MRI, including contrast agent and diffusion weighted ima-
ging) close to the start of treatment with ocrelizumab. The
evaluation should preferably be carried out by a (neuro-)
radiologist experienced in the diagnosis of inflammatory
diseases of the central nervous system. For patients with
a high risk of developing PML (positive anti-JCV antibo-
dies, treatment duration with natalizumab 2 years; or
previous immunosuppression), it is also recommended that
a cranial MRI be carried out after start of the treatment.
Additionally for this patient group, a lumbar puncture to
determine JC virus DNA, preferably in a high sensitivity
assay, is advisable prior to treatment start. Some centers
similarly perform lumbar puncture when switching from
fingolimod to ocrelizumab, but there is no consensus
regarding this approach among Swiss centers.
Attention should be paid to routine check-up for cancer
(in particular regular gynecological routine check-up) and
tumor aftercare. According to the Swiss information for
health-care professionals, women of child bearing potential
should use contraception while receiving ocrelizumab and
for 6 months after the last infusion; according to the SmPC
issued by EMA this interval is set to 12 months.
Concluding remarks
Different benefit-risk assessments but also procedural
aspects can lead to partly divergent approval.34 Staggered
submissions to the various regulatory authorities can lead
to different data availability according to the time of sub-
mission. This is important because not only the relevant
scientific data but also further aspects, for example, data
quality and product quality, are taken into account. Cul-
tural, political, legal, and country-specific priorities proba-
bly also play a role.34 Other countries (e.g. emerging/
developing countries) also refer to the Swiss approval. To
increase the transparency of the approval process, respec-
tive reports (Swiss Public Assessment Report, SwissPAR)
will be published as part of the revision of the Therapeutic
Products Act (TPA, Art. 67) from 2019.
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